
Morgan Stanley lowered the firm’s price target on Structure Therapeutics (GPCR) to $117 from $126 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| GPCR | Structure Therapeutics, Inc. Sponsored ADR | 17.36 | -17.52 | -50.23% |
| Name | Price | % Change | |
|---|---|---|---|
| $17.36 | -50.23% |

Morgan Stanley lowered the firm’s price target on Structure Therapeutics (GPCR) to $117 from $126 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate

Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ananda Ghosh from H.C. Wainwright maintained a Buy rating on the stock

In a report released on November 10, Evan Seigerman from BMO Capital reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a price target of $145.00. Evan Seigerman’s

Canaccord lowered the firm’s price target on Structure Therapeutics (GPCR) to $107 from $111 and keeps a Buy rating on the shares. The firm said Structure reported financial results and

Insiders have been trading these 5 stocks: (($SCCO)), (($TOL)), (($SPRU)), (($GPCR)) and (($VRSN)). Here is a breakdown of their recent trades and their value. Director Luis Miguel Palomino Bonilla’s move

WSW, NY, September 23rd, 2026, FinanceWire Entera Bio Ltd. (NASDAQ:ENTX) has been initiated with coverage by Cantor Fitzgerald, in a report titled “No More Needles! An Oral PTH For Osteoporosis”,

Structure Therapeutics, Inc. Sponsored ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from LifeSci Capital maintained a Buy rating on the stock

After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies sees the roughly 7% stock pullback following today’s data as “disconnected from

Clear Street says Structure Therapeutics (GPCR) announced “encouraging updates “across its obesity portfolio. ACCG-2671 is beginning to unlock value and aleniglipron’s 72-week open-label extension data is “strengthening its best-in-class oral

Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist, and aleniglipron, an oral, non-peptide,
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 12, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Sep 8, 2026 | ||||
| buy | Reiterated | Sep 8, 2026 | ||||
| buy | Reiterated | Sep 8, 2026 | ||||
| buy | Reiterated | Sep 8, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 4, 2027TBA | $1.30B | $-0.68 | $0.00 | -11.30 | -4.66 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.